Yangjie Wei, Ph.D.
University of Kansas
Lawrence, KS USA
Yangjie Wei is a recent graduate of the University of Kansas where he earned his Ph.D. in pharmaceutical chemistry. His doctoral research explores two different strategies -- polyvalent antigen display and the use of adjuvants – to enhance the immunogenicity of subunit vaccine candidates.
In 2017, Wei received a graduate student fellowship from the AAPS Foundation to support his research. He also worked on several side projects related to formulation development of biologics. He interned with the formulation group at Regeneron, studying the effects of formulation variables on the viscosity of a high-concentration mAb drug product during the summer of 2017. He defended his dissertation in early October 2018 and will join Boehringer Ingelheim Pharmaceuticals as a postdoctoral researcher working on biophysical analysis of novel therapeutic proteins.
Wei holds a master’s degree in industrial pharmacy from the University of Toledo, OH. His master’s thesis focused on masking the bitter taste of injectable lidocaine HCl formulation for dental procedures by formation of an inclusion complex with 2-hydroxylpropyl-β-cyclodextrin. He obtained his bachelor’s degree in pharmaceutics from China Pharmaceutical University in 2011.
Wei has served as a reviewer for several journals including Journal of Pharmaceutical Sciences, Journal of Pharmaceutical and Biomedical Analysis, Journal of Biotechnology and AAPS PharmSciTech.
SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members. > READ MORE
November 20, 2018